EP300 and breast cancer: Since inhibiting CBP/p300 by C646 also substantially decreased PI3K/Akt activation by CapG overexpression in breast cancer cells, targeting CBP/p300 may serve as an alternative strategy to counteract CapG-mediated paclitaxel resistance.